Boston Scientific Climbs
Boston Scientific (BSX ) announced positive nine-month results from its Taxus VI drug-eluting stent trial. S&P upgraded to buy from accumulate.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.